The Experts below are selected from a list of 210 Experts worldwide ranked by ideXlab platform
J. J. Gray - One of the best experts on this subject based on the ideXlab platform.
-
Epstein-Barr Virus infection in heart and heart-lung transplant recipients: incidence and clinical impact.
Journal of Heart and Lung Transplantation, 1995Co-Authors: J. J. Gray, P. Pavel, Jayan Parameshwar, Susan Stewart, Cary N, S.r. Large, Tim Wreghitt, Rosalind L Smyth, John WallworkAbstract:BACKGROUND: A retrospective serologic study was made of 67 heart-lung and 295 heart transplant recipients (with transplantations at Papworth Hospital, Cambridge, England) to determine the incidence and clinical impact of Epstein-Barr Virus infection. METHODS: Epstein-Barr Virus Capsid Antigen immunofluorescence tests were performed, and the antibody avidity was determined by modifying the washing procedure to include a mild reducing agent (8M urea). RESULTS: This testing showed that 6.0% of the patients had primary Epstein-Barr Virus infections, whereas 17.4% had the reactivation of a past infection. Primary infections were only detected in patients who were Epstein-Barr Virus antibody-negative before transplantation, who had received an organ from an Epstein-Barr Virus antibody-positive donor. Of the patients with serologically proven Epstein-Barr Virus infections, 52.9% had symptoms. Although these were generally mild, five heart and two heart-lung transplant recipients had malignant lymphoma and one heart and one heart-lung transplant recipient had lymphoproliferative disease after Epstein-Barr Virus infection. Additional four heart transplant recipients had lymphoma after transplantation. None of these four patients had evidence of active Epstein-Barr Virus infection; one was Epstein-Barr Virus antibody-negative during the study period and three had stable Epstein-Barr Virus Virus Capsid Antigen immunoglobulin G titers throughout. CONCLUSIONS: Epstein-Barr Virus infection in organ transplant recipients may lead on to life-threatening lymphoproliferative disease or lymphoma. For this reason it may be beneficial to monitor patients after transplantation for evidence of Epstein-Barr Virus infection and to follow the progress of those affected.
-
Epstein-Barr Virus infection in heart and heart-lung transplant recipients: incidence and clinical impact.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 1995Co-Authors: J. J. Gray, P. Pavel, Jayan Parameshwar, Susan Stewart, S.r. Large, Tim Wreghitt, Rosalind L Smyth, N R Cary, John WallworkAbstract:A retrospective serologic study was made of 67 heart-lung and 295 heart transplant recipients (with transplantations at Papworth Hospital, Cambridge, England) to determine the incidence and clinical impact of Epstein-Barr Virus infection. Epstein-Barr Virus Capsid Antigen immunofluorescence tests were performed, and the antibody avidity was determined by modifying the washing procedure to include a mild reducing agent (8M urea). This testing showed that 6.0% of the patients had primary Epstein-Barr Virus infections, whereas 17.4% had the reactivation of a past infection. Primary infections were only detected in patients who were Epstein-Barr Virus antibody-negative before transplantation, who had received an organ from an Epstein-Barr Virus antibody-positive donor. Of the patients with serologically proven Epstein-Barr Virus infections, 52.9% had symptoms. Although these were generally mild, five heart and two heart-lung transplant recipients had malignant lymphoma and one heart and one heart-lung transplant recipient had lymphoproliferative disease after Epstein-Barr Virus infection. Additional four heart transplant recipients had lymphoma after transplantation. None of these four patients had evidence of active Epstein-Barr Virus infection; one was Epstein-Barr Virus antibody-negative during the study period and three had stable Epstein-Barr Virus Virus Capsid Antigen immunoglobulin G titers throughout. Epstein-Barr Virus infection in organ transplant recipients may lead on to life-threatening lymphoproliferative disease or lymphoma. For this reason it may be beneficial to monitor patients after transplantation for evidence of Epstein-Barr Virus infection and to follow the progress of those affected.
-
The rapid serological diagnosis of infectious mononucleosis.
The Journal of infection, 1992Co-Authors: J. J. Gray, Jill Caldwell, Margaret SillisAbstract:Summary A total of 121 samples of serum collected from ioi patients was tested to determine the sensitivity and specificity of a commercial latex agglutination test for detecting infectious mononucleosis heterophile antibody, a commercial immunofluorescence test for detecting antibody to Epstein-Barr Virus Capsid Antigen and a rapid enzyme immunoassay for detecting antibody to Epstein—Barr Virus nuclear Antigen. Although the Epstein—Barr Virus Capsid Antigen IgM indirect immunofluorescence test proved to be the most sensitive, false-positive reactions were seen when samples collected from patients with cytomegaloVirus, hepatitis A Virus, parvoVirus and leptospira infection were tested. False-positive reactions were also seen with samples containing rheumatoid factor.
John Wallwork - One of the best experts on this subject based on the ideXlab platform.
-
Epstein-Barr Virus infection in heart and heart-lung transplant recipients: incidence and clinical impact.
Journal of Heart and Lung Transplantation, 1995Co-Authors: J. J. Gray, P. Pavel, Jayan Parameshwar, Susan Stewart, Cary N, S.r. Large, Tim Wreghitt, Rosalind L Smyth, John WallworkAbstract:BACKGROUND: A retrospective serologic study was made of 67 heart-lung and 295 heart transplant recipients (with transplantations at Papworth Hospital, Cambridge, England) to determine the incidence and clinical impact of Epstein-Barr Virus infection. METHODS: Epstein-Barr Virus Capsid Antigen immunofluorescence tests were performed, and the antibody avidity was determined by modifying the washing procedure to include a mild reducing agent (8M urea). RESULTS: This testing showed that 6.0% of the patients had primary Epstein-Barr Virus infections, whereas 17.4% had the reactivation of a past infection. Primary infections were only detected in patients who were Epstein-Barr Virus antibody-negative before transplantation, who had received an organ from an Epstein-Barr Virus antibody-positive donor. Of the patients with serologically proven Epstein-Barr Virus infections, 52.9% had symptoms. Although these were generally mild, five heart and two heart-lung transplant recipients had malignant lymphoma and one heart and one heart-lung transplant recipient had lymphoproliferative disease after Epstein-Barr Virus infection. Additional four heart transplant recipients had lymphoma after transplantation. None of these four patients had evidence of active Epstein-Barr Virus infection; one was Epstein-Barr Virus antibody-negative during the study period and three had stable Epstein-Barr Virus Virus Capsid Antigen immunoglobulin G titers throughout. CONCLUSIONS: Epstein-Barr Virus infection in organ transplant recipients may lead on to life-threatening lymphoproliferative disease or lymphoma. For this reason it may be beneficial to monitor patients after transplantation for evidence of Epstein-Barr Virus infection and to follow the progress of those affected.
-
Epstein-Barr Virus infection in heart and heart-lung transplant recipients: incidence and clinical impact.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 1995Co-Authors: J. J. Gray, P. Pavel, Jayan Parameshwar, Susan Stewart, S.r. Large, Tim Wreghitt, Rosalind L Smyth, N R Cary, John WallworkAbstract:A retrospective serologic study was made of 67 heart-lung and 295 heart transplant recipients (with transplantations at Papworth Hospital, Cambridge, England) to determine the incidence and clinical impact of Epstein-Barr Virus infection. Epstein-Barr Virus Capsid Antigen immunofluorescence tests were performed, and the antibody avidity was determined by modifying the washing procedure to include a mild reducing agent (8M urea). This testing showed that 6.0% of the patients had primary Epstein-Barr Virus infections, whereas 17.4% had the reactivation of a past infection. Primary infections were only detected in patients who were Epstein-Barr Virus antibody-negative before transplantation, who had received an organ from an Epstein-Barr Virus antibody-positive donor. Of the patients with serologically proven Epstein-Barr Virus infections, 52.9% had symptoms. Although these were generally mild, five heart and two heart-lung transplant recipients had malignant lymphoma and one heart and one heart-lung transplant recipient had lymphoproliferative disease after Epstein-Barr Virus infection. Additional four heart transplant recipients had lymphoma after transplantation. None of these four patients had evidence of active Epstein-Barr Virus infection; one was Epstein-Barr Virus antibody-negative during the study period and three had stable Epstein-Barr Virus Virus Capsid Antigen immunoglobulin G titers throughout. Epstein-Barr Virus infection in organ transplant recipients may lead on to life-threatening lymphoproliferative disease or lymphoma. For this reason it may be beneficial to monitor patients after transplantation for evidence of Epstein-Barr Virus infection and to follow the progress of those affected.
Luciano Zubaran Goldani - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of severe infectious mononucleosis with famciclovir.
The Journal of infection, 2002Co-Authors: Luciano Zubaran GoldaniAbstract:We report a patient with severe acute infectious mononucleosis who was successfully treated with famciclovir. A 15-year-old male was admitted with a 6-week history of fever, malaise, generalized lymphadenopathy, and hepatosplenomegaly, the patient was acutely ill with a temperature of 39.0 degrees C. Oropharingeal examination revealed enlarged tonsils partially obstructing the airways. EBV serology obtained during admission showed a positive Monospot test, Virus Capsid Antigen IgM, 1:320, Epstein-Barr nuclear and early Antigen, negative. After 72 hours of treatment with famciclovir (500 mg t.i.d.), the patient was afebrile with important regression of the lymphadenopathy, enlarged tonsils and hepatosplenomegaly. Because acute infectious mononucleosis may be associated with extensive and prolonged disease, the potential therapeutic role of famciclovir in the treatment of severe forms of the disease deserves further studies.
-
CASE REPORTS Treatment of Severe Infectious Mononucleosis with Famciclovir
2002Co-Authors: Luciano Zubaran GoldaniAbstract:We report a patient with severe acute infectious mononucleosis who was successfully treated with famciclovir. A 15-year-old male was admitted with a 6-week history of fever, malaise, generalized lymphadenopathy, and hepatosplenomegaly, the patient was acutely ill with a temperature of 39.0C. Oropharingeal examination revealed enlarged tonsils partially obstructing the airways. EBV serology obtained during admission showed a positive Monospot test, Virus Capsid Antigen IgM, 1:320, Epstein‐Barr nuclear and early Antigen, negative. After 72 hours of treatment with famciclovir (500 mg t.i.d.), the patient was afebrile with important regression of the lymphadenopathy, enlarged tonsils and hepatosplenomegaly. Because acute infectious mononucleosis may be associated with extensive and prolonged disease, the potential therapeutic role of famciclovir in the treatment of severe forms of the disease deserves further studies.
Shulin Chen - One of the best experts on this subject based on the ideXlab platform.
-
Preliminary evaluation of a candidate international reference for Epstein–Barr Virus Capsid Antigen immunoglobulin A in China
2020Co-Authors: Hao Chen, Qiaohua Zhong, Yanling Ding, Qi Chen, Ning Xue, Shulin ChenAbstract:Abstract Background: The detection of the Epstein–Barr Capsid Antigen (VCA) immunoglobulin A (IgA) is widely used inthe diagnosis of nasopharyngeal carcinoma (NPC),but a reference standard for evaluating the presence of VCA-IgA isnot yet available. Therefore, a reference standard is urgently needed for a uniform and quantitative detection of VCA-IgA.Methods: A mixed reference serum from three NPC patients diluted with healthy subject serum was made as a potential first international standard for VCA-IgA. VCA-IgA was detected in twenty NPC patients by four ELISA kits and two chemiluminescent immunoassays kits using the reference as a calibration curve. The performance of these six kits was evaluated, and the quantitative results were compared. Results: Our results showed a good linearity of the reference in different kits. Without reference, the difference of the total coefficient of variation (from 3.98% to 43.11%) and Within-run coefficient of variation (from 2.47% to 19.66%) was large in the 6 kits. The positive and negative coincidence rate between the 6 kits and indirect immunofluorescence for NPC diagnosis was 75% overall agreement, but a difference among the six kits was found, ranging from 55% to 90%. The concentration of VCA-IgA in the 20 NPC samples led in the division into three categories such as negative, low, or medium/high positive, but these concentrations were significantly different within these three categories depending on the kit used of the 6 considered. However,a good correlation (R2=0.986) was observed between Antu and Beier ELISA kits.Conclusions: The reference serum mightbe used as a reference standard for a better comparison of the results from different kits/laboratories.However, the quantitative results of some kits are still inconsistent due to the diversity of VCA Antigens.
-
Preliminary evaluation of a candidate international reference for Epstein–Barr Virus Capsid Antigen immunoglobulin A in China
Infectious agents and cancer, 2020Co-Authors: Hao Chen, Qiaohua Zhong, Yanling Ding, Qi Chen, Ning Xue, Shulin ChenAbstract:The detection of the Epstein-Barr Capsid Antigen (VCA) immunoglobulin A (IgA) is widely used in the diagnosis of nasopharyngeal carcinoma (NPC), but a reference standard for evaluating the presence of VCA-IgA is not yet available. Therefore, a reference standard is urgently needed for a uniform and quantitative detection of VCA-IgA. A mixed reference serum from three NPC patients diluted with healthy subject serum was made as a potential first international standard for VCA-IgA. VCA-IgA was detected in twenty NPC patients by four ELISA kits and two chemiluminescent immunoassays kits using the reference as a calibration curve. The performance of these six kits was evaluated, and the quantitative results were compared. Our results showed a good linearity of the reference in different kits. Without reference, the difference of the total coefficient of variation (from 3.98 to 43.11%) and Within-run coefficient of variation (from 2.47 to 19.66%) was large in the 6 kits. The positive and negative coincidence rate between the 6 kits and indirect immunofluorescence for NPC diagnosis was 75% overall agreement, but a difference among the six kits was found, ranging from 55 to 90%. The concentration of VCA-IgA in the 20 NPC samples led in the division into three categories such as negative, low, or medium/high positive, but these concentrations were significantly different within these three categories depending on the kit used of the 6 considered. However,a good correlation (R2 = 0.986) was observed between Antu and Beier ELISA kits. The reference serum mightbe used as a reference standard for a better comparison of the results from different kits/laboratories. However, the quantitative results of some kits are still inconsistent due to the diversity of VCA Antigens. © The Author(s) 2020.
-
preliminary evaluation of a candidate international reference for epstein barr Virus Capsid Antigen immunoglobulin a in china
Infectious Agents and Cancer, 2020Co-Authors: Hao Chen, Qiaohua Zhong, Yanling Ding, Qi Chen, Ning Xue, Shulin ChenAbstract:The detection of the Epstein–Barr Capsid Antigen (VCA) immunoglobulin A (IgA) is widely used in the diagnosis of nasopharyngeal carcinoma (NPC), but a reference standard for evaluating the presence of VCA-IgA is not yet available. Therefore, a reference standard is urgently needed for a uniform and quantitative detection of VCA-IgA. A mixed reference serum from three NPC patients diluted with healthy subject serum was made as a potential first international standard for VCA-IgA. VCA-IgA was detected in twenty NPC patients by four ELISA kits and two chemiluminescent immunoassays kits using the reference as a calibration curve. The performance of these six kits was evaluated, and the quantitative results were compared. Our results showed a good linearity of the reference in different kits. Without reference, the difference of the total coefficient of variation (from 3.98 to 43.11%) and Within-run coefficient of variation (from 2.47 to 19.66%) was large in the 6 kits. The positive and negative coincidence rate between the 6 kits and indirect immunofluorescence for NPC diagnosis was 75% overall agreement, but a difference among the six kits was found, ranging from 55 to 90%. The concentration of VCA-IgA in the 20 NPC samples led in the division into three categories such as negative, low, or medium/high positive, but these concentrations were significantly different within these three categories depending on the kit used of the 6 considered. However,a good correlation (R2 = 0.986) was observed between Antu and Beier ELISA kits. The reference serum mightbe used as a reference standard for a better comparison of the results from different kits/laboratories. However, the quantitative results of some kits are still inconsistent due to the diversity of VCA Antigens.
-
Preliminary evaluation of the candidate international reference for Epstein–Barr Virus Capsid Antigen immunoglobulin A in China
2020Co-Authors: Hao Chen, Qiaohua Zhong, Yanling Ding, Qi Chen, Ning Xue, Shulin ChenAbstract:Abstract Background: Epstein–Barr Capsid Antigen (VCA) immunoglobulin A (IgA) detection is widely used for nasopharyngeal carcinoma (NPC), but reference standard for VCA-IgA has not yet been determined. For uniform and quantitative detection of VCA- IgA, reference standard is in urgent need. Methods: A mixed reference serum from three patients with NPC diluted with healthy subjects serum was made as a possible first international standard for VCA-IgA. Four ELISA kits and two chemiluminescent immunoassays(CLIA) kits were used to detected VCA-IgA in twenty NPC patients using the reference as a calibration curve. The performance of six kits were evaluated, and the quantitative results were compared. Results: Our results shown the reference has good linearity in different kits. Without reference, the difference of total CV (from 3.98% to 43.11%) and Within-run CV(from 2.47% to 19.66%) was large in 6 kits. The positive and negative coincidence rate between 6 kits and IFA for NPC diagnosis was 75% overall agreement, but there was a difference among the six kits ranged from 55%-90%. Concentration of 20 NPC samples divided into three sample categories was shown significant difference in a few subgroup of 6 methods. But a good correlation (R2=986) was observed between Antu and Beier ELISA kits. Conclusions: The reference serum may be used as a reference standard and better compared results from different methods/laboratories. However, due to the diversity of VCA Antigens, the quantitative results of some kits are still inconsistent.
Jaap M. Middeldorp - One of the best experts on this subject based on the ideXlab platform.
-
Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr Virus Capsid Antigen complex
Journal of medical virology, 1993Co-Authors: W. M. J. Van Grunsven, A.j.j.m Nabbe, Jaap M. MiddeldorpAbstract:The molecular specificity of the IgG response against Epstein-Barr Virus (EBV) was studied in 345 randomly collected sera of normal healthy individuals. The sera were tested on immunoblots containing Antigens of the cell line HH514.c16 (a superinducible derivate of P3HR1), noninduced or induced for the expression of early Antigens (EA) or viral Capsid Antigens (VCA), and from the EBV-negative cell line Ramos-Nut. This study reveals a remarkable similar Antigen recognition pattern of IgG class antibodies in sera of healthy EBV carriers. The protein bands recognized predominantly have molecular weights of 18 kD, 36/38 kD, 40 kD, 72 kD, and 160 kD. The 72 kD and 36/38 kD bands were identified as EBNA1 and "Zebra," respectively, using reading frame-specific antisera. The bands at 160 kD (major Capsid protein), 40 kD, and 18 kD were identified as VCA-class proteins. Of all EBV-seropositive sera tested, 98% reacted with either p18 or p40 or both. The synthesis of the Antigens p18 and p40 was inhibited by phosphonoacetic acid, indicating that these were true late proteins. The detection of p18 and p40 in purified virion and Capsid preparations confirms that these proteins are structural components of viral Capsid Antigen complex.
